GLP-1 Medications for Prediabetes: Can They Reverse It?

More than 96 million American adults — roughly one in three — have prediabetes, and the vast majority don't know it. Left untreated, prediabetes progresses to type 2 diabetes within 5 to 10 years in up to 70% of cases. But here's the encouraging news: prediabetes is not a life sentence. With the right intervention, it can be reversed — and GLP-1 receptor agonists are emerging as one of the most powerful tools available.

Originally developed for type 2 diabetes, GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have demonstrated remarkable effects on blood sugar regulation, insulin sensitivity, and body weight — all of which are central to prediabetes. This article explores what the research says about GLP-1 medications and prediabetes, and whether they might be right for you.

What Is Prediabetes and Why Does It Matter?

Prediabetes is defined by blood glucose levels that are higher than normal but not yet high enough to qualify as type 2 diabetes. It's measured using three primary tests:

• Fasting blood glucose: 100–125 mg/dL (normal is under 100; diabetes is 126+)
• HbA1c: 5.7–6.4% (normal is under 5.7%; diabetes is 6.5%+)
• Oral glucose tolerance test (OGTT): 140–199 mg/dL at 2 hours

Prediabetes reflects early insulin resistance — a state where your cells no longer respond efficiently to insulin, forcing the pancreas to produce more to compensate. Over time, the pancreatic beta cells become exhausted and blood sugar rises progressively toward full diabetes.

The stakes are significant even before a diabetes diagnosis. People with prediabetes already face higher risks of cardiovascular disease, neuropathy, kidney dysfunction, and fatty liver disease. Addressing prediabetes early isn't just about avoiding diabetes — it's about protecting your overall metabolic health for decades to come.

How GLP-1 Medications Work on Blood Sugar

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the gut after eating. It plays multiple roles in glucose regulation:

• Stimulates insulin secretion in response to food — in a glucose-dependent manner, reducing hypoglycemia risk
• Suppresses glucagon, the hormone that signals the liver to release stored glucose
• Slows gastric emptying, blunting post-meal glucose spikes
• Acts on the brain to reduce appetite and food intake

GLP-1 receptor agonists like semaglutide mimic this hormone but with a much longer half-life, providing sustained effects over days rather than minutes. The result is improved glucose control across the entire day — not just at mealtimes.

For people with prediabetes, this mechanism is particularly valuable. The glucose-dependent insulin stimulation means these medications correct blood sugar without driving it dangerously low, making them far safer than older diabetes drugs in pre-diabetic states.

What the Research Shows: GLP-1s and Prediabetes

The clinical evidence for GLP-1 medications in prediabetes is compelling and growing.

The SCALE Obesity and Prediabetes Trial

One landmark study published in the New England Journal of Medicine examined liraglutide (an early GLP-1 medication) in adults with prediabetes and obesity. After three years, participants receiving liraglutide were 66% less likely to develop type 2 diabetes compared to those receiving a placebo. More strikingly, 66% of liraglutide-treated participants actually regressed from prediabetes to normal blood glucose — compared to just 36% in the placebo group.

The SURMOUNT Trials With Tirzepatide

The SURMOUNT trial program for tirzepatide (the dual GLP-1/GIP receptor agonist) showed even more dramatic results. In the SURMOUNT-1 trial, participants without diabetes who had obesity achieved an average of 20.9% body weight reduction. Among participants who had prediabetes at baseline, nearly 95% had normal blood glucose by the end of the study period — a remarkable reversal rate.

Semaglutide in Prediabetes

Data from the STEP (Semaglutide Treatment Effect in People with Obesity) trials showed that among participants with prediabetes at baseline, 84% achieved normoglycemia (normal blood sugar) after 68 weeks on semaglutide 2.4 mg — compared to just 48% on placebo. This effect was driven by a combination of weight loss, improved insulin sensitivity, and the direct glycemic effects of semaglutide itself.

Why Weight Loss Matters (But Isn't the Whole Story)

A 5–10% reduction in body weight is generally sufficient to significantly reduce prediabetes progression risk. GLP-1 medications routinely produce this level of weight loss — and often far more. But researchers have found that the blood sugar improvements from GLP-1s are actually greater than would be predicted by weight loss alone.

This suggests these medications have direct glycemic effects independent of weight reduction — including improvements in pancreatic beta cell function, reduced hepatic glucose output, and enhanced insulin sensitivity at the cellular level. For someone with prediabetes, this multi-mechanistic approach offers an advantage over lifestyle interventions alone.

That said, lifestyle factors remain crucial. The most successful outcomes in clinical trials combined GLP-1 therapy with dietary guidance and moderate physical activity. Think of GLP-1 medications as powerful accelerators of metabolic improvement — not replacements for healthy habits.

Are You a Candidate for GLP-1 Therapy for Prediabetes?

Currently, GLP-1 medications are FDA-approved for type 2 diabetes (Ozempic, Mounjaro) and chronic weight management in adults with a BMI ≥30, or ≥27 with a weight-related condition (Wegovy, Zepbound). Prediabetes itself is considered a weight-related condition that can qualify patients for weight management medications.

You may be a candidate if you:

• Have confirmed prediabetes (HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL)
• Have a BMI of 27 or higher
• Have tried lifestyle modifications without achieving adequate blood sugar normalization
• Want to reduce your risk of progressing to type 2 diabetes
• Are concerned about cardiovascular or metabolic health more broadly

A telehealth physician can review your lab values, health history, and goals to determine the most appropriate approach — whether that's GLP-1 therapy, lifestyle optimization, or a combination.

Practical Considerations: Starting GLP-1 Therapy for Prediabetes

If you and your physician decide GLP-1 therapy is appropriate, here's what to expect:

Starting dose and titration: Both semaglutide and tirzepatide are started at low doses and gradually increased over weeks to months. This titration process minimizes side effects — particularly the nausea and gastrointestinal symptoms that are most common in the early weeks.

Monitoring: Your physician will likely recheck your HbA1c and fasting glucose at 3- to 6-month intervals to track progress and adjust dosing as needed.

Duration of therapy: GLP-1 medications are typically used long-term. If stopped without maintaining the lifestyle changes and metabolic improvements, blood sugar and weight often return toward baseline. Some patients achieve sufficient metabolic health improvements that they can step down under physician supervision.

Cost and access: Coverage for GLP-1 medications varies by insurance plan. Compounded semaglutide and tirzepatide offer more affordable alternatives for patients who are candidates but face cost barriers.

The Bottom Line

Prediabetes is a critical window of opportunity — a time when metabolic dysfunction is still reversible with the right interventions. GLP-1 receptor agonists have demonstrated impressive ability to normalize blood glucose, restore insulin sensitivity, and prevent progression to type 2 diabetes in clinical trials.

If you've been told your blood sugar is "borderline" or you've received a prediabetes diagnosis, don't wait. The evidence increasingly supports early, proactive intervention — and modern GLP-1 medications offer one of the most effective tools available. A conversation with a knowledgeable telehealth provider is the first step toward turning prediabetes around before it becomes something more serious.